Cooperative Agreement 2018ARBXK030

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $844,475 to the University of Alabama at Birmingham (UAB) to test a bundled intervention aimed at increasing treatment uptake for patients with opioid use disorder (OUD) and nonfatal opioid overdoses after emergency department (ED) discharge. The proposed intervention combines telehealth, peer support, buprenorphine prescribing, and linkage to...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $594,122 to Boulder Care, Inc. to develop and test telehealth workflows for delivering buprenorphine treatment for opioid use disorder (OUD) in vulnerable settings. The project aims to address barriers to OUD treatment access by providing smartphones and connectivity to individuals in high-risk situations, such as jails/prisons, emergency...

This federal Project Grant award of $193,752 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the implementation and testing of a video-coaching intervention called THRIVE to promote positive parenting behaviors among mothers with opioid use disorder (OUD). The 5-year project, which began on April 15, 2025, aims to integrate this parenting intervention into pediatric primary care settings to increase accessibility and...

This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,717,104 over 3 years to adapt and pilot test a Youth Overdose Prevention Toolkit for use in pediatric healthcare settings. The project aims to develop practical, developmentally-appropriate guidance for delivering evidence-based overdose prevention interventions such as naloxone, take-home drug testing, harm reduction education, and...

This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...

The National Institutes of Health's National Institute on Drug Abuse awarded New York University School of Medicine a $1,446,310 Project Grant under the Drug Abuse and Addiction Research Programs to adapt an evidence-based posttraumatic stress disorder intervention for polysubstance use populations receiving treatment for opioid use disorder. Specifically, the award will support adapting an existing trauma-focused therapy, Skills Training in Affective and Interpersonal Regulation with...

This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $235,542 to Brigham & Women's Hospital Inc. to conduct a double-blind, randomized clinical trial evaluating the safety of using extended-release buprenorphine (XR-BUP) as a low-dose induction strategy for patients with opioid use disorder. The study aims to determine if XR-BUP can be safely administered before the emergence of opioid withdrawal...

The National Institute on Drug Abuse (NIDA) awarded a $193,336 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Trustees of Dartmouth College to evaluate a pharmacist-integrated model of opioid use disorder (OUD) treatment in primary care settings. The goal is to investigate if this model can increase the co-prescribing of naloxone, the opioid overdose antidote, to patients receiving medication treatment for OUD. The research project aims to: 1) describe federal,...

The Ohio Department of Health was awarded a $6 million project grant from the Department of Justice's Bureau of Justice Assistance under the Comprehensive Opioid, Stimulant, and other Substances Use Program to implement evidence-based substance use disorder treatment and harm reduction services in six counties. The three-year award will support expanding harm reduction activities and education targeting Black and Hispanic populations in high-risk areas; improving access to medication-assisted...